Active Ingredient History
Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acne Vulgaris (Phase 2)
Adenocarcinoma (Phase 2)
Adenocarcinoma, Clear Cell (Phase 2)
Adenoma, Islet Cell (Phase 2)
Adrenal Gland Neoplasms (Phase 3)
Adrenocortical Carcinoma (Phase 3)
Aged (Phase 2)
Allergy and Immunology (Phase 1)
Alzheimer Disease (Phase 1)
Anthracyclines (Phase 2)
Appendiceal Neoplasms (Phase 1)
Astrocytoma (Phase 2)
Beckwith-Wiedemann Syndrome (Phase 3)
Bile Duct Neoplasms (Phase 2)
Biomarkers (Phase 2)
Bone Neoplasms (Phase 2)
Brain Neoplasms (Phase 3)
Breast Diseases (Phase 2)
Breast Neoplasms (Phase 4)
Breast Neoplasms, Male (Phase 2)
Brenner Tumor (Phase 1)
Burkitt Lymphoma (Phase 4)
Carcinoma (Phase 3)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Basal Cell (Phase 1/Phase 2)
Carcinoma, Ductal (Phase 2)
Carcinoma, Hepatocellular (Phase 4)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 3)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Carcinosarcoma (Phase 2)
Cardiotoxicity (Phase 3)
Castleman Disease (Phase 1)
Chemoembolization, Therapeutic (Phase 2)
Cholangiocarcinoma (Phase 2)
Chondrosarcoma (Phase 3)
Chondrosarcoma, Mesenchymal (Phase 2/Phase 3)
Choroid Plexus Neoplasms (Phase 3)
Cognition Disorders (Phase 2)
Cognitive Dysfunction (Phase 1)
Colonic Neoplasms (Early Phase 1)
Colorectal Neoplasms (Phase 3)
Cyclophosphamide (Phase 3)
Depression (Phase 2)
Dermatofibrosarcoma (Phase 3)
Dermatology (Phase 2/Phase 3)
Desmoplastic Small Round Cell Tumor (Phase 2)
Diffuse Intrinsic Pontine Glioma (Phase 2)
Down Syndrome (Phase 3)
Doxorubicin (Phase 3)
Drug Evaluation (Phase 4)
Drugs, Investigational (Phase 3)
Drug Therapy (Phase 2/Phase 3)
Edema (Phase 2)
Endometrial Neoplasms (Phase 3)
Endoscopy (Phase 2)
Enteropathy-Associated T-Cell Lymphoma (Phase 4)
Erythema (Phase 2)
Esophageal Neoplasms (Phase 2)
Exploratory Behavior (Phase 2)
Fallopian Tube Neoplasms (Phase 3)
Fever (Phase 3)
Fibromatosis, Aggressive (Phase 1)
Fibrosarcoma (Phase 3)
Fusion Proteins, bcr-abl (Phase 2)
Gallbladder Neoplasms (Phase 2)
Ganglioneuroblastoma (Phase 3)
Gastrointestinal Neoplasms (Phase 1/Phase 2)
Gastrointestinal Stromal Tumors (Phase 1)
Genetic Predisposition to Disease (Phase 3)
Genital Neoplasms, Female (Phase 3)
Geriatrics (Phase 3)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Hamartoma (Phase 4)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 1)
Hemangiosarcoma (Phase 2)
Hematologic Diseases (Phase 3)
Hematologic Neoplasms (Phase 4)
Hepatoblastoma (Phase 3)
Herpesvirus 4, Human (Phase 3)
Herpesvirus 8, Human (Phase 2)
Histiocytic Sarcoma (Phase 2/Phase 3)
HIV (Phase 2)
HIV Infections (Phase 4)
Hodgkin Disease (Phase 4)
HTLV-I Infections (Phase 1)
Hypertrophy (Phase 3)
Immunoglobulin Light-chain Amyloidosis (Phase 2)
Immunoglobulin Light Chains (Phase 2)
Immunoglobulins (Phase 3)
Inflammatory Breast Neoplasms (Phase 3)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 1/Phase 2)
Kidney Diseases (Phase 3)
Kidney Neoplasms (Phase 3)
Lapatinib (Phase 2)
Leiomyosarcoma (Phase 3)
Lenalidomide (Phase 2)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 1/Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)
Leukemia, Lymphoid (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 4)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Plasma Cell (Phase 2)
Leukemia, T-Cell (Phase 2/Phase 3)
Liposarcoma (Phase 3)
Liposarcoma, Myxoid (Phase 2)
Liver Neoplasms (Phase 3)
Lung Diseases (Phase 3)
Lung Neoplasms (Phase 3)
Lymphangiosarcoma (Phase 2)
Lymphatic Diseases (Phase 2)
Lymph Nodes (Phase 3)
Lymphohistiocytosis, Hemophagocytic (Phase 3)
Lymphoma (Phase 4)
Lymphoma, AIDS-Related (Phase 2)
Lymphoma, B-Cell (Phase 4)
Lymphoma, B-Cell, Marginal Zone (Phase 3)
Lymphoma, Extranodal NK-T-Cell (Phase 3)
Lymphoma, Follicular (Phase 4)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Lymphoma, Large-Cell, Anaplastic (Phase 4)
Lymphoma, Large-Cell, Immunoblastic (Phase 4)
Lymphoma, Mantle-Cell (Phase 4)
Lymphoma, Non-Hodgkin (Phase 4)
Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1/Phase 2)
Lymphoma, Primary Effusion (Phase 2)
Lymphoma, T-Cell (Phase 4)
Lymphoma, T-Cell, Cutaneous (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 4)
Lymphomatoid Granulomatosis (Phase 2)
Lymphoproliferative Disorders (Phase 4)
Malnutrition (Phase 2)
Mediastinal Neoplasms (Phase 4)
Melanoma (Phase 1/Phase 2)
Meningeal Carcinomatosis (Phase 2)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 3)
Mouth Neoplasms (Phase 2)
Multiple Myeloma (Phase 4)
Mutation (Phase 2)
Mycoses (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Myeloma Proteins (Phase 3)
Myeloproliferative Disorders (Phase 2)
Myosarcoma (Phase 2)
Nasopharyngeal Carcinoma (Phase 2)
Nausea (Phase 3)
Neoadjuvant Therapy (Phase 2/Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasms ()
Neoplasms by Histologic Type (Phase 1)
Neoplasms, Connective and Soft Tissue (Phase 2/Phase 3)
Neoplasms, Connective Tissue (Phase 2/Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplasms, Neuroepithelial (Phase 2)
Nerve Sheath Neoplasms (Phase 2/Phase 3)
Neuroblastoma (Phase 3)
Neuroectodermal Tumors (Phase 3)
Neuroectodermal Tumors, Primitive (Phase 1)
Neuroendocrine Tumors (Phase 3)
Neurofibromatosis 1 (Phase 2)
Neurofibrosarcoma (Phase 2/Phase 3)
Neutropenia (Phase 3)
N-Myc Proto-Oncogene Protein (Phase 1/Phase 2)
Obesity (Phase 4)
Oligodendroglioma (Phase 1)
Oncogenes (Phase 2)
Optic Nerve Glioma (Phase 1)
Osteosarcoma (Phase 3)
Ovarian Diseases (Phase 2)
Ovarian Neoplasms (Phase 4)
Pain (Phase 2)
Palmar Plate (Phase 3)
Pancreatic Neoplasms (Phase 2)
Patient Participation (Phase 1/Phase 2)
Pediatrics (Phase 3)
Pelvic Neoplasms (Phase 3)
Peritoneal Neoplasms (Phase 3)
Perivascular Epithelioid Cell Neoplasms (Phase 2/Phase 3)
Pheochromocytoma (Phase 3)
Phosphatidylinositol 3-Kinases (Phase 1/Phase 2)
Plasmablastic Lymphoma (Phase 2)
Plasmacytoma (Phase 3)
Progression-Free Survival (Phase 2/Phase 3)
Prostatic Neoplasms (Phase 3)
Prosthesis Failure (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 2)
Radiotherapy (Phase 2)
Rectal Neoplasms (Early Phase 1)
Retinal Neoplasms (Phase 3)
Retinoblastoma (Phase 3)
Retroperitoneal Neoplasms (Phase 1)
Rhabdomyosarcoma (Phase 4)
Safety (Phase 4)
Salivary Gland Neoplasms (Phase 2)
Sarcoma (Phase 4)
Sarcoma, Alveolar Soft Part (Phase 2/Phase 3)
Sarcoma, Clear Cell (Phase 2/Phase 3)
Sarcoma, Ewing (Phase 3)
Sarcoma, Kaposi (Phase 3)
Sarcoma, Synovial (Phase 3)
Sclerosis (Phase 2)
Sepsis (Phase 3)
Sezary Syndrome (Phase 1)
Skin Diseases (Phase 2)
Skin Neoplasms (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 3)
Solitary Fibrous Tumors (Phase 2)
Stomach Neoplasms (Phase 2)
Stomatitis (Phase 2)
Survival (Phase 2)
Testicular Neoplasms (Phase 3)
Thalidomide (Phase 3)
Thrombocytopenia (Phase 2)
Thromboembolism (Phase 2)
Thymoma (Phase 2)
Thyroid Neoplasms (Phase 2)
Translocation, Genetic (Phase 2)
Transplantation (Phase 1/Phase 2)
Treatment Refusal (Phase 2)
Triple Negative Breast Neoplasms (Phase 3)
Tumor Suppressor Protein p53 (Phase 2)
Ureteral Neoplasms (Phase 3)
Urethral Neoplasms (Phase 3)
Urinary Bladder Neoplasms (Phase 3)
Urogenital Neoplasms (Phase 1)
Uterine Cervical Neoplasms (Phase 2)
Uterine Neoplasms (Phase 3)
Vaginal Neoplasms (Phase 2)
Vulvar Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
Wilms Tumor (Phase 4)
Zollinger-Ellison Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
